Bladder Cancer Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Bladder cancer is the most common malignancy of the urinary tract, with approximately 614,000 new cases diagnosed globally per year (2022 data). Urothelial carcinoma (formerly called transitional cell carcinoma) accounts for approximately 90% of all bladder cancers; rarer subtypes include squamous cell carcinoma (associated with chronic infection or stone irritation) and adenocarcinoma. The disease is strongly associated with cigarette smoking, which accounts for approximately 50% of all cases, and with occupational exposure to aromatic amines in rubber, dye, paint, and chemical industries. The male-to-female ratio is approximately 3:1.

Bladder cancer is classified into non-muscle-invasive bladder cancer (NMIBC — stages Ta, T1, and CIS) and muscle-invasive bladder cancer (MIBC — stages T2–T4). Approximately 75% of bladder cancers present as NMIBC. The critical distinction determines the treatment pathway: NMIBC is managed with endoscopic resection (TURBT) combined with intravesical therapy, while MIBC requires more aggressive treatment — neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy (surgical removal of the bladder and regional lymph nodes), or bladder-preserving chemoradiation as an alternative.

All bladder cancer diagnoses and treatment plans are discussed at multidisciplinary uro-oncology team (MDT) meetings including urological surgeons, medical oncologists, radiation oncologists, radiologists, and pathologists. Treatment decisions are individualised based on tumour stage, grade, number and size of tumours, prior recurrences, and patient performance status and comorbidities.

Non-muscle-invasive bladder cancer (NMIBC) comprises three risk categories under EAU guidelines. Low-risk NMIBC includes primary solitary Ta low-grade tumours managed with TURBT and a single immediate post-operative intravesical chemotherapy instillation (mitomycin C). Intermediate-risk NMIBC includes recurrent, multifocal, or larger low-grade tumours managed with TURBT plus 1-year adjuvant intravesical chemotherapy (mitomycin C or epirubicin). High-risk NMIBC includes T1 high-grade tumours, carcinoma in situ (CIS — flat, high-grade intraepithelial neoplasm), and T1 tumours with CIS, managed with TURBT followed by 1–3 years of intravesical BCG (Bacillus Calmette-Guerin) immunotherapy — the most effective agent for preventing recurrence and progression of high-risk NMIBC.

Muscle-invasive bladder cancer (T2–T4, N0–N3) requires systemic staging (CT of chest, abdomen, pelvis with bladder protocol; bone scan if clinical indication) and is treated with curative intent using cisplatin-based neoadjuvant chemotherapy (MVAC or gemcitabine-cisplatin) followed by radical cystectomy. Bladder-preserving trimodality therapy (maximal TURBT followed by concurrent chemoradiation) is an oncologically equivalent alternative for selected patients who are not surgical candidates or who choose to preserve the bladder. Immune checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab) are approved for platinum-refractory metastatic urothelial cancer and, in cisplatin-ineligible patients, as first-line treatment of high PD-L1 expressing metastatic bladder cancer.

All patients diagnosed with bladder cancer are candidates for treatment, with the specific treatment modality determined by staging, grade, prior treatment history, and patient fitness. Radical cystectomy candidates should have ECOG performance status 0–2, adequate organ function (renal, hepatic, cardiac, pulmonary), and motivation for the significant surgery and recovery involved. Neoadjuvant cisplatin-based chemotherapy is offered to all cisplatin-eligible cT2–T4aN0M0 patients, as it improves 5-year overall survival by approximately 5–8% in randomised trials.

Patients unfit for cisplatin (creatinine clearance <60 mL/min, ECOG PS >2, significant hearing loss, neuropathy, or NYHA class III/IV heart failure) may receive carboplatin-based regimens, though these have lower efficacy. For BCG therapy in high-risk NMIBC, active immunosuppression, active tuberculosis, and gross haematuria at the time of instillation are contraindications. Elderly patients and those with comorbidities require careful assessment — radical cystectomy carries significant perioperative risk (30-day mortality approximately 2–3% at high-volume centres) and should be performed by experienced uro-oncological surgeons at volume-outcomes-validated centres.

Transurethral resection of bladder tumour (TURBT) is the foundational procedure for all stages of bladder cancer diagnosis and treatment. For NMIBC, complete macroscopic resection of all visible tumours is essential, followed by random mucosal biopsies of suspicious areas. Re-TURBT within 4–6 weeks is recommended for all T1 tumours, inadequately resected tumours, and cases where muscle was not sampled in the initial specimen, as it upstages approximately 20–30% of T1 lesions to T2 disease and changes management. Enhanced cystoscopy (photodynamic diagnosis with hexaminolevulinate/Hexvix) improves CIS detection by approximately 15–25% and is performed at specialist bladder cancer centres.

Intravesical BCG therapy — the most important adjuvant treatment for high-risk NMIBC — is instilled via urinary catheter weekly for 6 weeks (induction), followed by 3-weekly maintenance cycles at 3, 6, 12, 18, 24, 30, and 36 months (EAU 3-year maintenance protocol). BCG reduces recurrence by 32–43% and progression by 37% compared with TURBT alone in high-risk NMIBC meta-analyses. Radical cystectomy with pelvic lymph node dissection is performed open, laparoscopically, or robotically (robotic-assisted laparoscopic radical cystectomy — RARC). Robotic surgery is increasingly used at major centres for reduced blood loss and faster recovery, though long-term oncological equivalence with open surgery is established in published series.

For NMIBC, TURBT with appropriate intravesical therapy produces excellent long-term outcomes in low- and intermediate-risk disease, with 10-year disease-specific survival exceeding 90% for Ta low-grade tumours. High-risk NMIBC treated with BCG carries a 5-year overall survival of approximately 70–80%, with 25–30% eventually requiring cystectomy due to recurrence, progression, or BCG failure. Complete response to BCG at 3 months is achieved in 60–75% of patients with CIS.

For muscle-invasive bladder cancer, neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy achieves 5-year overall survival of approximately 50–60% for pT2 disease and 35–45% for pT3–T4 pathological stage. Bladder-preserving trimodality therapy (TMT) achieves equivalent 5-year survival of 50–60% in selected stage T2 patients, with 75–80% of surviving patients retaining their native bladder. Checkpoint inhibitor pembrolizumab improves overall survival versus chemotherapy in second-line platinum-refractory metastatic urothelial cancer.

BCG intravesical therapy causes cystitis symptoms (frequency, urgency, dysuria, haematuria) in 60–80% of patients during induction — typically self-limiting within 48–72 hours after each instillation. Systemic BCG infection (BCG-itis or BCG sepsis) is a rare but serious complication occurring in 0.1–0.4% of patients, presenting with fever, rigors, and systemic illness; it is treated with anti-tuberculous therapy (rifampicin, isoniazid) and is potentially life-threatening if not promptly recognised. BCG is absolutely contraindicated in immunosuppressed patients.

Radical cystectomy carries significant surgical morbidity: 30-day complication rates of 30–60% (predominantly urinary tract infections, ileus, and wound complications), 90-day complication rates of approximately 50–65%, and 30-day mortality of 2–3% at specialist centres (higher at lower-volume centres). Urinary diversion (ileal conduit, orthotopic neobladder, or continent cutaneous diversion) is performed simultaneously and has its own specific complications including uretero-intestinal anastomotic stricture, metabolic acidosis from ileal segment use, and complications specific to continent diversions. Sexual dysfunction (erectile dysfunction in men; urinary incontinence and sexual dysfunction in women) is a near-universal consequence of standard radical cystectomy.

NMIBC surveillance following TURBT involves cystoscopy at 3 months post-resection (to confirm complete resection and detect early recurrence), then as determined by risk stratification: every 3 months for 2 years (high-risk), every 6 months for 2 years (intermediate-risk), and at 12 months then annually (low-risk). Upper tract imaging (CT urogram) is performed at regular intervals for high-risk disease. Urine cytology is performed at each cystoscopy visit.

After radical cystectomy, patients are followed with CT chest/abdomen/pelvis every 3–6 months for 2 years, then annually. Urinary diversion function is monitored with renal function, electrolytes (metabolic acidosis monitoring), and annual renal ultrasound. After orthotopic neobladder, voiding diary and post-void residual measurements guide continence management. All bladder cancer patients should receive smoking cessation counselling and support, as smoking increases recurrence risk in addition to causing primary disease.

Bladder cancer treatment costs vary enormously by stage. TURBT with intravesical mitomycin C costs USD 5,000–15,000 in the US per episode; a full BCG induction plus 3-year maintenance course costs USD 15,000–30,000 in drug costs alone, plus surveillance cystoscopy costs. Radical cystectomy with urinary diversion in the US costs USD 50,000–120,000 or more for the surgical episode. Checkpoint inhibitor therapy for metastatic disease costs USD 150,000–200,000 per year.

Medical tourism for bladder cancer treatment is common, particularly for high-volume but cost-intensive procedures like radical cystectomy. In India, radical cystectomy with ileal conduit at JCI-accredited centres costs USD 8,000–18,000 — an 80–85% saving versus US costs. BCG intravesical therapy and TURBT surveillance cystoscopy costs are similarly dramatically lower. Major Indian centres including Tata Memorial Hospital Mumbai (India's premier public cancer hospital), Apollo, Fortis, and Manipal have specialist uro-oncological surgery programmes. Thailand and Turkey offer cystectomy at USD 12,000–25,000. The combination of lower procedural costs and world-class specialist teams makes India a particularly compelling option for the extensive treatment journey of high-risk bladder cancer.

For high-risk NMIBC where BCG therapy has failed (BCG-unresponsive CIS or T1), systemic pembrolizumab is FDA-approved as bladder-sparing immunotherapy, achieving complete response in approximately 41% of patients at 3 months. Intravesical gemcitabine plus docetaxel, intravesical nadofaragene firadenovec (a gene therapy), and novel intravesical agents are in clinical trials or recently approved for BCG-unresponsive NMIBC in specific jurisdictions.

For muscle-invasive disease in patients refusing or unfit for radical cystectomy, trimodality therapy (maximal TURBT + concurrent cisplatin-based chemosensitisation + pelvic radiotherapy) is an oncologically valid bladder-preserving alternative, achieving comparable 5-year survival to cystectomy in appropriately selected T2 patients with complete response. Partial cystectomy is rarely applicable, limited to solitary MIBC in the bladder dome without CIS elsewhere. Immunotherapy combinations (checkpoint inhibitor doublets, antibody-drug conjugates) are transforming the treatment landscape for metastatic urothelial cancer and are the subject of multiple Phase III trials.